White House Targets PBM Reform Amid Escalating Drug Pricing Concerns

The White House is taking aim at pharmacy benefit managers (PBMs) as part of its ongoing efforts to address escalating drug pricing concerns. PBMs, which act as intermediaries between drug manufacturers, insurers, and pharmacies, have come under scrutiny for their role in driving up prescription drug costs. The Biden administration is now pushing for reforms to increase transparency and accountability in the PBM industry, with the goal of lowering drug prices for consumers.